Clindamycin-13C,d3
Modify Date: 2024-01-10 21:00:12
Clindamycin-13C,d3 structure
|
Common Name | Clindamycin-13C,d3 | ||
|---|---|---|---|---|
| CAS Number | 2140264-63-5 | Molecular Weight | 428.99 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C1713CH30D3ClN2O5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Clindamycin-13C,d3Clindamycin-13C,d3 is the 13C- and deuterium labeled. Clindamycin is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla)[1]. |
| Name | Clindamycin-13C,d3 |
|---|
| Description | Clindamycin-13C,d3 is the 13C- and deuterium labeled. Clindamycin is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[59]. |
| References |
| Molecular Formula | C1713CH30D3ClN2O5S |
|---|---|
| Molecular Weight | 428.99 |